Armetheon, Inc. is a privately held San Francisco Bay area-based biopharmaceutical company with late-stage clinical drug candidates in development for cardiovascular diseases. The company was founded in 2011 by experienced biotech entrepreneurs and drug developers.
Armetheon’s two late-stage small molecule drug candidates are for use in the areas of oral anti-coagulation and anti-arrhythmia for atrial fibrillation.
The company was founded with the idea that drug innovations can happen by building on the success of proven medications. We create solutions that are within the same class of medication and that utilize the same mechanism of action as existing therapies.
This development approach has the ...
Armetheon, Inc. is a privately held San Francisco Bay area-based biopharmaceutical company with late-stage clinical drug candidates in development for cardiovascular diseases. The company was founded in 2011 by experienced biotech entrepreneurs and drug developers.
Armetheon’s two late-stage small molecule drug candidates are for use in the areas of oral anti-coagulation and anti-arrhythmia for atrial fibrillation.
The company was founded with the idea that drug innovations can happen by building on the success of proven medications. We create solutions that are within the same class of medication and that utilize the same mechanism of action as existing therapies.
This development approach has the ability to offer peace of mind to patients while benefitting physicians, who may wish to reduce safety concerns, side effects and adverse events for their patients.
-
Number of Employees:
25-100
-
Annual Revenue:
$1-10 Million